Multiformat T-Cell-Engaging Bispecific Antibodies Targeting Human Breast Cancers
Dr. Yu Cao, Dr. Jun Y. Axup, Dr. Jennifer S. Y. Ma, Dr. Rongsheng E. Wang, Dr. Seihyun Choi, Dr. Virginie Tardif, Dr. Reyna K. V. Lim, Holly M. Pugh, Dr. Brian R. Lawson, Gus Welzel, Dr. Stephanie A. Kazane, Dr. Ying Sun, Dr. Feng Tian, Shailaja Srinagesh, Dr. Tsotne Javahishvili, Prof. Peter G. Schultz and Dr. Chan Hyuk Kim
Article first published online: 27 APR 2015 | DOI: 10.1002/anie.201500799
Bispecific antibodies are highly effective for targeting breast cancer cells with antigens of low abundance. It is suggested that the monovalent BiFab in the absence of an Fc domain may be the best bispecific antibody format to trigger antigen-dependent T-cell activation and target tumor eradication for low or heterogeneous Her2-expressing cancers.